Page last updated: 2024-11-04

phenolsulfonphthalein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenolsulfonphthalein, also known as phenolsulfonephthalein (PSP), is a dye used in medicine to measure kidney function. It is injected intravenously and its excretion in urine is measured over time. PSP is synthesized by reacting phthalic anhydride with phenol in the presence of sulfuric acid. The resulting compound is a red dye that is filtered by the glomeruli of the kidneys and excreted in the urine. The amount of PSP excreted in the urine is directly proportional to the glomerular filtration rate (GFR), which is a measure of kidney function. PSP is used to diagnose and monitor kidney disease, and to assess the effectiveness of treatment. The importance of PSP in research lies in its ability to provide a reliable and accurate measure of kidney function. This information can be used to identify individuals at risk for kidney disease, to monitor the progression of kidney disease, and to evaluate the effectiveness of treatment. PSP is also used in research to study the mechanisms of kidney function.'

Phenolsulfonphthalein: Red dye, pH indicator, and diagnostic aid for determination of renal function. It is used also for studies of the gastrointestinal and other systems. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phenol red : 3H-2,1-Benzoxathiole 1,1-dioxide in which both of the hydrogens at position 3 have been substituted by 4-hydroxyphenyl groups. A pH indicator changing colour from yellow below pH 6.8 to bright pink above pH 8.2, it is commonly used as an indicator in cell cultures and in home swimming pool test kits. It is also used in the (now infrequently performed) phenolsulfonphthalein (PSP) test for estimation of overall blood flow through the kidney. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4766
CHEMBL ID258921
CHEBI ID31991
SCHEMBL ID17836
MeSH IDM0016521

Synonyms (115)

Synonym
AC-18338
BIDD:ER0046
phenol, 4,4'-(1,1-dioxido-3h-2,1-benzoxathiol-3-ylidene)bis-
phenol, 4,4'-(3h-2,1-benzoxathiol-3-ylidene)di-, s,s-dioxide
phenol, 4,4'-(3h-2,1-benzoxathiol-3-ylidene)bis-, (s,s-dioxide)
phenol, 4,4-(3h-2,1-benzoxathiol-3-ylidene)di-, s-s-dioxide
nsc 10459
3h-2,1-benzoxathiole, 3,3-bis(4-hydroxyphenyl)-, 1,1-dioxide
phenolsulphonphthalein
4,4'-(3h-2,1-benzoxathiol-3-ylidene)diphenol s,s-dioxide
psp (indicator)
einecs 205-609-7
brn 0326470
143-74-8
phenol,4'-(3h-2,1-benzoxathiol-3-ylidene)bis-, s,s-dioxide
3h-2, 3,3-bis(4-hydroxyphenyl)-, 1,1-dioxide
nsc-10459
phenolsulfonphthalein
fenolipuna
phenol red
sulphonthal
phenolsulfonephthalein
phenol,4-(3h-2,1-benzoxathiol-3-ylidene)di-, s,s-dioxide
sulfonphthal
psp
nsc10459 ,
p. s. p.
phenol,4-(3h-2,1-benzoxathiol-3-ylidene)di-, s-s-dioxide
phenol,4'-(3h-2,1-benzoxathiol-3-ylidene)di-, s,s-dioxide
sulphental
NCGC00013109
STK364540
4-[3-(4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenol
phenol, 4,4'-(3h-2,1-benzoxathiol-3-ylidene)bis-,s,s-dioxide (9ci)
phenol red, powder, bioreagent, suitable for cell culture
phenolsulfonphthalein (tn)
phenolsulfonphthalein (jp17/nf)
D01200
phenol red, acs reagent
NCI10459
NCI60_000111
NCISTRUC2_000839
NCISTRUC1_001090
4,4'-(1,1-dioxido-3h-2,1-benzoxathiole-3,3-diyl)diphenol
NCGC00096230-01
phenol, 4,4'-(3h-2,1-benzoxathiol-3-ylidene)bis-, s,s-dioxide
P-2800
CHEMBL258921
phenosulfophthalein
AKOS000592531
3,3-bis(p-hydroxyphenyl)-3h-2,1-benzoxathiole 1,1-dioxide
4,4'-(3h-2,1-benzoxathiol-3-ylidene)bisphenol s,s-dioxide
CHEBI:31991 ,
alpha-hydroxy-alpha,alpha-bis(p-hydroxyphenyl)-o-toluenesulfonic acid gamma-sultone
P0101
P0703
P0100
BBL000596
3,3-bis(4-hydroxyphenyl)benzo[c]1,2-oxathiolene-1,1-dione
unii-i6g9y0j1oj
5-19-03-00457 (beilstein handbook reference)
i6g9y0j1oj ,
phenolsulfonphthalein [jan:nf]
dtxsid8022408 ,
tox21_303570
cas-143-74-8
NCGC00257424-01
dtxcid202408
NCGC00013109-01
tox21_110012
CCG-36909
NCGC00013109-02
NCGC00013109-03
FT-0631835
phenolsulfonphthalein [mart.]
phenolsulfonphthalein [inci]
phenolsulfonphthalein [vandf]
3,3-bis(4-hydroxyphenyl)-3h-2,1-benzoxathiole 1,1-dioxide
phenolsulfonphthalein [mi]
phenolsulfonphthalein [who-dd]
phenolsulfonphthalein [jan]
phenolsulfonphthalein [ep monograph]
phenol-red
SCHEMBL17836
tox21_110012_1
phenolred
phenol red, recrystallized
P-2801
phenol red, psp
phenol red indicator
4,4'-(3h,2,1-benzoxathiol-3-ylidene)bisphenol s,s-dioxide
AB00444024_03
mfcd00003552
3,3-bis(4-hydroxyphenyl)-3h-benzo[c][1,2]oxathiole 1,1-dioxide
SR-01000357546-1
sr-01000357546
phenol red, jis special grade
phenol red, p.a., acs reagent
c19h14o5s
Q418719
Z56768517
VS-00652
3,3-bis(4-hydroxyphenyl)-3h-2,1??-benzoxathiole-1,1-dione
DB13212
4-[3-(4-hydroxyphenyl)-1,1-dioxo-2,1lambda6-benzoxathiol-3-yl]phenol
AMY22406
BRD-K79892937-001-01-7
D70382
A884896
phenol red acs grade
phenol red solution
CS-0010076
HY-D0169
3,3-bis(4-hydroxyphenyl)-3h-2,1lambda6-benzoxathiole-1,1-dione
EN300-6492950

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In the present study, safe and effective ionic liquids for transdermal absorption were obtained as salts generated by a neutralization reaction between highly biocompatible aliphatic carboxylic acids (octanoic acid or isostearic acid) and aliphatic amines (diisopropanolamine or triisopropanolamine) (Medrx Co."( The molecular assembly of the ionic liquid/aliphatic carboxylic acid/aliphatic amine as effective and safety transdermal permeation enhancers.
Kubota, K; Shibata, A; Yamaguchi, T, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
"05) differences were not detected in pharmacokinetic values of either group."( Phenolsulfonphthalein pharmacokinetics and renal morphologic changes in adult pony mares with gentamicin-induced nephrotoxicosis.
Cooley, AJ; Hinchcliff, KW; MacWilliams, PS; McGuirk, SM, 1989
)
1.72
" Pharmacokinetic analysis revealed that tubular secretion is the predominant route of excretion, and that secretion is inhibited by PSP."( Physiologically based pharmacokinetic model for the renal clearance of salicyluric acid and the interaction with phenolsulfonphthalein in the dog.
Russel, FG; van Ginneken, CA; Wouterse, AC,
)
0.34
" Pharmacokinetic analysis revealed that tubular secretion is the predominant route of excretion, and that secretion is inhibited by probenecid and SUA."( Physiologically based pharmacokinetic model for the renal clearance of phenolsulfonphthalein and the interaction with probenecid and salicyluric acid in the dog.
Russel, FG; van Ginneken, CA; Wouterse, AC, 1987
)
0.51
"A physiologically based pharmacokinetic model was developed to describe the absorption and disposition of chlortetracyline (CTC) in the healthy and diseased (fowl cholera) turkey."( The pharmacokinetics of chlortetracycline orally administered to turkeys: influence of citric acid and Pasteurella multocida infection.
Dyer, DC; Glatz, CE; Pollet, RA, 1985
)
0.27
" In conclusion, the enhancement of PSP mucosal absorption by C10 and its derivatives is consistent with a pharmacokinetic model, assuming that the enhanced membrane permeability of PSP depends on the enhancer disappearance kinetics from the loop and its calcium ion sequestration capacity."( Pharmacokinetic analysis of the absorption enhancing action of decanoic acid and its derivatives in rats.
Higashi, Y; Kamata, A; Murakami, T; Takahashi, K; Yata, N; Yumoto, R, 1994
)
0.29
" Pharmacokinetic analysis revealed that there was a correlation between tumor weight and the rate constants of transfer from the poorly-perfused region to the well-perfused region, and between the rate constants of transfer from the well-perfused region to the venous outflow and dosing ratios into the well-perfused region."( Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system.
Hashida, M; Nomura, T; Saikawa, A; Sezaki, H; Takakura, Y; Yamashita, F, 1996
)
0.29
"5 and 20 mg/kg), the drug was rapidly absorbed, and Cmax was reached 2 h after dosing."( Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles.
Iwaki, M; Kasutani, M; Ogiso, T; Tanaka, H; Tanino, T, 2001
)
0.31
"The objective of this study was to evaluate the drug delivery advantage to the unilateral kidney by direct drug application to the rat kidney surface based on a physiological pharmacokinetic model."( Delivery advantage to the unilateral kidney by direct drug application to the kidney surface in rats and pharmacokinetic verification based on a physiological model.
Fumoto, S; Kamenosono, M; Kuma, A; Mukai, T; Nakamura, J; Nakashima, M; Nishida, K; Sasaki, H, 2005
)
0.33

Bioavailability

The permeability of phenolsulfonphthalein (phenol red) was examined as an index of an assessment of gastrointestinal mucosal damage in-vivo.

ExcerptReferenceRelevance
"The influence of the intermediate products of riboflavine photolysis on the absorption of poorly absorbed water-soluble drugs from the rat small intestine has been examined using an in situ recirculation technique."( An anomalous effect of the intermediate products of riboflavine photolysis on the intestinal absorption of poorly absorbed water-solbule drug in rats.
Ghazy, FS; Kimura, T; Muranishi, S; Sezaki, H, 1975
)
0.25
" When (35S)PR solution was injected through a tracheal cannula in control animals and the percentage of the tracheal cannula in control animals and the percentage of the dose unabsorbed plotted semilogarithmically against time, an apparent first-order absorption rate was obtained."( Effect of pulmonary edema on drug transport and binding in rat lung.
Gardiner, TH; Goodman, FR, 1977
)
0.26
" The 600-mg dose caused a decrease in drug bioavailability as measured by the total amount excreted in 24 hr."( Effect of surfactants on absorption through membranes V: Concentration-dependent effect of a bile salt (sodium deoxycholate) on absorption of a poorly absorbable drug, phenolsulfonphthalein, in humans.
Gouda, MW; Khalafalah, N; Khalil, SA, 1977
)
0.45
" The barbital absorption rate constant in deficient animals increased compared to control values."( Effect of alpha tocopherol (vitamin E) deficiency on intestinal transport of passively absorbed drugs.
Meshali, MM; Nightingale, CH, 1976
)
0.26
"Apparent intestinal permeability was determined indirectly by orally administering a poorly absorbed dye, phenol red, to rats and measuring its recovery in feces and in urine."( Effects of certain dietary fibers on apparent permeability of the rat intestine.
Chang, GW; Shiau, SY, 1986
)
0.27
"The permeability of phenolsulfonphthalein(phenol red), a poorly absorbed drug, was examined as an index of an assessment of gastrointestinal mucosal damage in-vivo."( An assessment of indomethacin-induced gastrointestinal mucosal damage in-vivo: enhancement of urinary recovery after oral administration of phenolsulfonphthalein in rats.
Heya, T; Kimura, T; Nakamura, J; Ohtsuka, N; Sezaki, H; Takada, S; Yamamoto, A, 1983
)
0.79
" The absolute bioavailability after vaginal administration of the 5% citric acid solution was 16."( Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats II: mechanism of absorption enhancement with organic acids.
Mima, H; Okada, H; Yamazaki, I; Yashiki, T, 1983
)
0.27
"The permeability of gastric wall barrier to phenolsulfonphthalein (phenol red), a poorly absorbed drug, was examined as an index of an assessment of gastric mucosal damages in vivo."( An assessment of gastric ulcers in vivo: enhancement of urinary recovery after oral administration of phenolsulfonphthalein in rats.
Hamaura, T; Heya, T; Kimura, T; Nakamura, J; Ohtsuka, N; Sezaki, H; Takada, S; Ueda, S; Yamamoto, A, 1984
)
0.74
" The bioavailability of both antibiotics appeared to depend on the concentration of the adjuvant in the microenema, the dosage form used in these experiments."( Enhanced rectal absorption of cefmetazole and cefoxitin in the presence of epinephrine metabolites in rats and a high-performance liquid chromatographic assay for cephamycin antibiotics.
Higuchi, T; Nishihata, T; Rytting, JH; Takahagi, H; Tomida, H; Yamamoto, M, 1984
)
0.27
" The Pa values of various hydrophilic compounds with different molecular weights were also estimated from their rectal bioavailability in the presence of C10."( Decanoic acid induced enhancement of rectal absorption of hydrophilic compounds in rats.
Hattori, T; Higashi, Y; Murakami, T; Takahashi, K; Yata, N; Yumoto, R, 1994
)
0.29
" Both the absorption rate constant KA and the plasma phenol red concentration were measured."( Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility.
Curatolo, W; Milisen, WB; Swenson, ES, 1994
)
0.29
" Their absorption rate from the peritoneal cavity was faster after intraperitoneal administration to the liver surface than that after intraperitoneal administration to the distal small intestine, as shown by the increase in maximum concentration and decrease in mean residence time in plasma."( Absorption of phenol red and bromphenol blue as model drugs from the peritoneal cavity around the liver surface in rats.
Amagishi, H; Nakamura, J; Nishida, K; Sasaki, H, 1995
)
0.29
" The overestimated plasma profile of propranolol suggests that the low bioavailability of propranolol is a result of first-pass metabolism by the intestine wall and the liver, because the calculated absolute absorption is almost perfect."( Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability.
Haruta, S; Higaki, K; Kimura, T; Kurosaki, Y; Sawamoto, T, 1997
)
0.3
" In an attempt to develop therapeutic agents which would maintain the pharmacological profiles of endogeneous neuroactive steroids but with increased oral bioavailability and reduced metabolic liability, we explored simple substitutions at the 3 beta-position of the endogenous neuroactive steroid, 3 alpha-hydroxy-5 alpha-pregnan-20-one (3 alpha, 5 alpha-P)."( Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593.
Belluzzi, J; Gee, KW; Hawkinson, JE; Hogenkamp, D; Lan, NC; Stein, L; Upasani, R; Wieland, S; Wood, PL, 1997
)
0.3
" Papp of IDM was greater than that of TAT, indicating that the order corresponded with that of in vivo bioavailability after oral administration of their PEG 600 solutions."( Evaluation of absorbability of poorly water-soluble drugs: validity of the use of additives.
Hayashi, M; Sudo, R; Takahashi, M; Watanabe, E, 2000
)
0.31
"Without changing the nitrogen absorptive balance, sucrose markedly affected the bioavailability profile, which is governed by gastric emptying."( Postprandial modulation of dietary and whole-body nitrogen utilization by carbohydrates in humans.
Benamouzig, R; Luengo, C; Mahé, S; Mariotti, F; Tomé, D, 2000
)
0.31
" At higher concentrations, the absorption rate would be limited by saturation of the carriers."( Nickel absorption and distribution from rat small intestine in situ.
Arnich, N; Burnel, D; Cunat, L; Joyeux, M; Lanhers, MC, 2000
)
0.31
" The decrease in absorption rate was characterized by a pharmacokinetic analysis of the plasma concentration profile."( Effect of viscous additives on drug absorption from the liver surface in rats using phenol red as a model.
Kawakami, S; Mukai, T; Nakakoga, Y; Nakamura, J; Nishida, K; Sakaeda, T; Sasaki, H; Sato, N, 2000
)
0.31
" The bioavailability of EPN after oral dosing was 41 and 40%."( Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles.
Iwaki, M; Kasutani, M; Ogiso, T; Tanaka, H; Tanino, T, 2001
)
0.31
" The calculated absorption rate constants (Ka) after continuous microinstillation of phenolsulphonphthalein based on a two-compartment model with first-order absorption were higher than those after bolus instillation on the liver and small intestinal serosal surface at either instillation concentration."( Effect of instillation method on the absorption of phenolsulphonphthalein as a model drug from the liver and small intestinal serosal surface in rats.
Kawakami, S; Mukai, T; Nakamura, J; Nakashima, M; Nishida, K; Sakaeda, T; Sasaki, H; Yoshida, Y, 2001
)
0.31
" The absorption rate constant (ka) for Compound I was calculated."( Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model.
Rinaldi, MT; Sutton, SC; Vukovinsky, KE, 2001
)
0.31
" The absorption rate - time profiles calculated by deconvolution method showed that C12 takes effect most rapidly and efficiently."( Estimation of absorption enhancement by medium-chain fatty acids in rat large intestine.
Higaki, K; Kimura, T; Ogawara, K; Sone, M; Yata, T,
)
0.13
" Although the absorption rate was increased in the CCl(4) group, whereas slightly retarded absorption was observed in GAL group, there should be no serious problem for the clinical use of liver surface application."( Influence of liver disease on phenolsulfonphthalein absorption from liver surface to examine possibility of direct liver surface application for drug targeting.
Honda, T; Nakamura, J; Nakashima, M; Nishida, K; Sasaki, H, 2003
)
0.61
" The release rate correlated with the rate of absorption of water."( Development of implant tablet for a week-long sustained release.
Machida, Y; Onishi, H; Takahashi, M, 2004
)
0.32
"It is known that secretory transport limits the oral bioavailability of certain drugs."( Characterization of secretory intestinal transport of phenolsulfonphthalein.
Chiba, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Miyazaki, K; Shimamoto, S; Sugawara, M, 2005
)
0.58
" In this study, the in vivo results clearly show that the absorption rate of ketoprofen is not dissolution limited; therefore ketoprofen would be essentially equivalent to Class I drugs and could be considered for waiver of bioavailability and bioequivalence testing."( Rapid in vivo dissolution of ketoprofen: implications on the biopharmaceutics classification system.
Amidon, GL; Granero, GE; Ramachandran, C, 2006
)
0.33
"To evaluate absorption barrier recovery in the gastrointestinal tract after treatment with a penetration enhancer by using a poorly absorbed marker and correlate results with morphological recovery."( Evaluation of mucosal damage and recovery in the gastrointestinal tract of rats by a penetration enhancer.
Albrecht, R; Bleher, R; Burnette, R; Kandela, A; Narkar, Y; Robinson, JR, 2008
)
0.35
"Absorption barrier recovery could be measured using a poorly absorbed marker."( Evaluation of mucosal damage and recovery in the gastrointestinal tract of rats by a penetration enhancer.
Albrecht, R; Bleher, R; Burnette, R; Kandela, A; Narkar, Y; Robinson, JR, 2008
)
0.35
"Various mechanisms can influence the intestinal absorption and oral bioavailability of drugs."( Contribution of multidrug resistance-associated protein 2 to secretory intestinal transport of organic anions.
Chiba, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M, 2008
)
0.35
" The absorption rate coefficients of all the assayed compounds did not show statistically significant differences between male and female rats consequently all the individual values were combined to compare between reabsorption methods."( Validation of phenol red versus gravimetric method for water reabsorption correction and study of gender differences in Doluisio's absorption technique.
Bermejo, M; Gonzalez-Alvarez, I; Gonzalez-Alvarez, M; Tuğcu-Demiröz, F, 2014
)
0.4
"We evaluated the effect of whey protein hydrolysates (WPH) on the water absorption rate in the small intestine using a rat small intestine perfusion model."( Whey protein hydrolysates enhance water absorption in the perfused small intestine of anesthetized rats.
Ito, K; Itoh, H; Noma, T; Oda, M; Yamaguchi, M; Yamaji, T, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
") dosing at 10 mg/kg body weight."( Pharmacokinetics and excretion of phenol red in the channel catfish.
Khoo, L; Plakas, SM; Stehly, GR, 1992
)
0.28
" Following BMY-25368 administration, hydrogen ion concentration was decreased and mean pH was higher than baseline values in a dose-response pattern."( Effects of a histamine type-2 receptor antagonist (BMY-25368) on gastric secretion in horses.
Dreyfuss, DJ; Orsini, JA; Spencer, PA; Uhlman, R; Vecchione, J, 1991
)
0.28
" Dose-response tests estimated that the maximally effective intravenous dose of pentagastrin was between 3 and 6 micrograms."( Basal and pentagastrin-stimulated gastric secretion in young horses.
Campbell-Thompson, ML; Merritt, AM, 1990
)
0.28
" CDE had a similar effect on peroxide production, but the dose-response curves suggested that only the high-molecular-weight polymers of tannin present in the CDE were able to enhance peroxide production."( Modulation of inflammatory cell function by cotton bract tannin: changes in the capacity of alveolar macrophages and neutrophils to produce hydrogen peroxide.
Rohrbach, MS; Vuk-Pavlović, Z, 1990
)
0.28
" 24 h treatment of pituitary cell cultures with increasing concentrations of Phr led to a stimulatory effect on GnRH-stimulated LH secretion an effect that occurred at 10 microM got maximal at 100 microM and was lost at higher concentrations resulting in a bell-shaped dose-response curve."( Weak estrogenic activity of phenol red in the pituitary gonadotroph: re-evaluation of estrogen and antiestrogen effects.
Emons, G; Knuppen, R; Ortmann, O; Sturm, R, 1990
)
0.28
" During dosing with omeprazole, basal gastric acid output diminished by 94%, and pentagastrin-stimulated acid output by 97%."( Repeated high oral doses of omeprazole do not affect intrinsic factor secretion: proof of a selective mode of action.
Den Hollander, W; Festen, HP; Meuwissen, SG; Tuynman, HA, 1989
)
0.28
" Tolerance to the acute effects of morphine on phenol red disposition is probably due to lessened response of blood flow or tubular function in chronically dosed mice."( Tolerance to morphine effects on renal disposition of xenobiotics in mice.
Garty, M; Hurwitz, A, 1986
)
0.27
"We describe a new method of drug dosage adjustment."( A new dosing regimen in renal insufficiency: application to cephalexin.
Akagi, K; Hori, R; Kamiya, A; Nakano, H; Nihira, H; Okumura, K, 1985
)
0.27
" The bioavailability of both antibiotics appeared to depend on the concentration of the adjuvant in the microenema, the dosage form used in these experiments."( Enhanced rectal absorption of cefmetazole and cefoxitin in the presence of epinephrine metabolites in rats and a high-performance liquid chromatographic assay for cephamycin antibiotics.
Higuchi, T; Nishihata, T; Rytting, JH; Takahagi, H; Tomida, H; Yamamoto, M, 1984
)
0.27
" Pharmacokinetic analysis revealed that there was a correlation between tumor weight and the rate constants of transfer from the poorly-perfused region to the well-perfused region, and between the rate constants of transfer from the well-perfused region to the venous outflow and dosing ratios into the well-perfused region."( Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system.
Hashida, M; Nomura, T; Saikawa, A; Sezaki, H; Takakura, Y; Yamashita, F, 1996
)
0.29
" The dose-response effects of phenol red were compared directly to those of E2."( Estrogen mitogenic action. III. is phenol red a "red herring"?
Moreno-Cuevas, JE; Sirbasku, DA,
)
0.13
" The bioavailability of EPN after oral dosing was 41 and 40%."( Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles.
Iwaki, M; Kasutani, M; Ogiso, T; Tanaka, H; Tanino, T, 2001
)
0.31
"A certain dosage of single leaf Asarum himalaicum caused acute renal failure in rabbits."( [Influence of single leaf Asarum himalaicum on renal function of rabbits].
Huang, SZ; Liu, JJ; Ming, HX, 2004
)
0.32
" It may also be used as a reliable technique to predict the fraction of dose absorbed following oral administration of drug in solution or regular release dosage form in human."( Predicting human intestinal permeability using single-pass intestinal perfusion in rat.
Azarmi, Y; Barzegar, S; Barzegar-Jalali, M; Islambolchilar, Z; Tajerzadeh, H; Valizadeh, H; Zakeri-Milani, P, 2007
)
0.34
"The comparison between the same dosage MJH and GJH showed the result had significant dissimilarity, the role intensity of MJH was bigger than that of GJH."( [Comparison on dissolving sputum and anti-inflammation of "mao ju hong" and "guang ju hong"].
Chen, Z; Lin, L; Zhang, X, 2004
)
0.32
" The model was validated using GI local concentration of phenol red in human GI tract, which was directly measured by human GI intubation study after oral dosing of non-absorbable phenol red."( Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time.
Amidon, GL; Baker, JR; Frances, A; Hasler, W; Jackson, T; Koenigsknecht, M; Marciani, L; Pai, A; Sun, D; Tsume, Y; Wen, B; Wysocki, J; Yu, A, 2017
)
0.46
" We advanced from a one-compartmental design of the stomach to a much more appropriate, multi-compartmental 'mixing tank' gastric model that reflects drug distribution along the different regions of the stomach as a consequence of randomly dosing relative to the different contractile phases of the migrating motor complex (MMC)."( Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach.
Amidon, GE; Amidon, GL; Baker, JR; Benninghoff, G; Bermejo, M; Dickens, J; Fan, J; Frances, A; Hasler, WL; Hens, B; Koenigsknecht, MJ; Lee, A; Lionberger, R; Löbenberg, R; Paixão, P; Salehi, N; Shedden, K; Sun, D; Talattof, A; Tsume, Y; Wen, B; Wysocki, J; Yu, A, 2018
)
0.48
" The validated methods were applied to the analysis of PEN-citrate in the dosage form and human serum samples where the drug was successfully resolved from the pharmaceutical additives and serum components with recoveries ≥98."( Extraction-free spectrophotometric assay of the antitussive drug pentoxyverine citrate using sulfonephthalein dyes.
Elfeky, SA; Issa, YM; Mohamed, SH, 2019
)
0.51
" The changes in colour showed a clear dose-response relationship compounds and enabled determination of the minimum inhibitory concentration."( A microtiter plate-based quantitative method to monitor the growth rate of dermatophytes and test antifungal activity.
Bolhuis, A; Delgado-Charro, B; Ho, FK, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
two-colour indicatorA colour indicator that possesses a different colour on each side of the transition interval.
acid-base indicatorAn acid or base which exhibits a colour change on neutralization by the basic or acidic titrant at or near the equivalence point of a titration.
diagnostic agentA substance administered to aid diagnosis of a disease.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
2,1-benzoxathiole
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
sultoneAn intramolecular cyclic ester of a hydroxy sulfonic acid, analogous to lactone.
arenesulfonate esterAn organosulfonic ester resulting from the formal condensation of an arenesulfonic acid with the hydroxy group of an alcohol, enol, phenol or heteroarenol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Regucalcin in proximal tubule epithelial kidney cells2415

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency15.42260.007215.758889.3584AID1224835; AID624030
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency15.84890.35487.935539.8107AID624170
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency0.19950.00137.762544.6684AID914; AID915
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency24.54540.01237.983543.2770AID1645841
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency61.40100.001530.607315,848.9004AID1224841; AID1224842; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency33.62270.000229.305416,493.5996AID1259244; AID1259248; AID743079; AID743080
GVesicular stomatitis virusPotency1.94970.01238.964839.8107AID1645842
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency30.10650.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency24.541219.739145.978464.9432AID1159509
Histone H2A.xCricetulus griseus (Chinese hamster)Potency52.91510.039147.5451146.8240AID1224845
cytochrome P450 2C9 precursorHomo sapiens (human)Potency6.30960.00636.904339.8107AID883
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency10.18150.005612.367736.1254AID624032
lethal factor (plasmid)Bacillus anthracis str. A2012Potency2.51190.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency30.63790.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency1.94970.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency1.94970.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency30.63790.001551.739315,848.9004AID1259244
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency6.30960.00638.235039.8107AID883
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency1.94970.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency1.94970.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1818651Permeability coefficient across apical to basolateral side in human Caco-2 cells by HPLC-UV analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia.
AID322955Inhibition of synthetic amyloid beta-42 oligomerization by ELISA2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1707770Inhibition of amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 50 uM by Thioflavin T based fluorometric assay relative to control2021European journal of medicinal chemistry, Feb-15, Volume: 212Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer's disease.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID322957Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1820953Inhibition of amyloid beta (1 to 42 ) (unknown origin) aggregation at 20 umol/L incubated for 24 hrs by thioflavin-T fluorescence method relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease.
AID322958Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (944)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990421 (44.60)18.7374
1990's177 (18.75)18.2507
2000's170 (18.01)29.6817
2010's133 (14.09)24.3611
2020's43 (4.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.57 (24.57)
Research Supply Index6.93 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index50.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (2.70%)5.53%
Reviews10 (1.00%)6.00%
Case Studies4 (0.40%)4.05%
Observational1 (0.10%)0.25%
Other957 (95.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]